Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting

Two additional investigator-sponsored trial posters featuring tegavivint clinical studies in EGFR-mutated NSCLC and pediatric osteosarcoma will also be presented HOUSTON, May 4, 2026 /PRNewswire/ -- Iterion Therapeutics, a clinical-stage biopharmaceutical company developing novel...